Novo Nordisk built modern obesity pharmacology. Liraglutide came first in 2009, with Saxenda following in 2014. Semaglutide split into three products — Ozempic for type-2 diabetes, Wegovy for obesity, and Rybelsus as the oral form. The 2025 and 2026 cadence has been about defending that position against Lilly's tirzepatide while moving the next generation forward.
The May 6 Q1 2026 print landed strong: net sales DKK 96.82B (+24% YoY), operating profit DKK 59.62B (+54%). Wegovy pill drove the upside with DKK 2.26B (~$354M) in Q1 — almost 2× analyst consensus — on roughly 1.3 million Q1 prescriptions and 2 million-plus cumulative since the January 5 launch. CEO Mike Doustdar told CNBC on May 6 that Wegovy holds 65% of all new US GLP-1 prescriptions, calling the moment a 'turnaround situation.' NovoCare priced the 1.5 mg starter at $149/month and moved the 4 mg dose from $149 to $199 effective April 15. On May 1, Novo officially retired the Rybelsus US brand and re-launched the same molecule as Ozempic Pill at 1.5/4/9 mg with improved-absorption reformulation across 70,000+ pharmacies. Wegovy HD 7.2 mg launched April 7 with a STEP UP 21% mean weight loss anchor. Full-year guidance tightened to a 4–12% sales-and-operating-profit decline (from the prior 5–13%) — Jefferies pushed back that the lower-end guidance was not lifted enough to be a positive surprise.
The pipeline gets harder from here. CagriSema (cagrilintide + semaglutide) failed to match Zepbound in February's head-to-head readout (23% vs 25.5%), and the Q1 documents disclosed Novo has discontinued the single-chamber co-formulation device — the dual-chamber injectable system continues with the original FDA filing already submitted and a higher-dose Phase 3 trial slated for H2 2026. Petrelintide and amycretin-prodrug sit further back. The Indian semaglutide patent expired in March 2026 and licensed generics from Biocon and Dr. Reddy's followed within weeks.
International milestones continued through Q2 2026. Japan's MHLW granted Novo Nordisk a partial change approval on June 19, 2026 making Wegovy the first approved MASH treatment in Japan (without cirrhosis, moderate-to-advanced fibrosis), co-promoted with Sumitomo Pharma under the October 2025 co-promotion agreement and based on ESSENCE Phase 3 Part 1 data. France joined the UK and Switzerland with public-insurance reimbursement effective June 15, 2026 at 65% Sécurité Sociale coverage, and the UAE became the first ex-US Wegovy pill launch on June 3.
September 7, 2026 was a split-decision day. STEP Young reported that 40.4% of children aged 6 to under 12 with obesity achieved a BMI below the obesity threshold at week 68 on semaglutide plus lifestyle modification, versus 0% on placebo, with safety consistent with adult and adolescent trials and no signal on growth or pubertal development — potentially opening a supplemental filing path to extend Wegovy below its current 12-and-older label. On the same day the company confirmed it had terminated the HERMES and ATHENA Phase 3 heart failure trials of ziltivekimab (anti-IL-6 monoclonal antibody) early after a data monitoring committee ruled the studies unlikely to succeed, following the June 2026 ZEUS miss. A post-acute heart-failure study of ziltivekimab remains ongoing, but the non-GLP-1 diversification story has narrowed further.
Analyst sentiment split further into the week of September 8-11. HSBC raised its Novo Nordisk target to DKK 320 from DKK 300 (Hold, September 9) after early-week positive newsflow, and Barclays cut its target from DKK 310 to DKK 300 (Equal Weight, September 8) after the STEP Young + ziltivekimab split announcement. Morgan Stanley's Thibault Boutherin then downgraded Novo to Underweight from Equal-weight on Friday September 11, cutting the price target to DKK 250 (implying more than 10% downside) on concerns that current valuation does not reflect the subdued mid-term growth outlook or the semaglutide patent-cliff impact on Novo's terminal value. Morgan Stanley flagged that semaglutide is expected to account for approximately 75% of 2026 sales, with loss of exclusivity beginning in 2031, and cited weaker U.S. Wegovy pill script momentum after a stronger first half. Novo shares closed the week down 2.8% in Copenhagen at DKK 278.2 and 3.1% in Frankfurt at EUR 36.89. The company continued executing the DKK 15 billion share repurchase programme (DKK 9.02 billion completed through September 4).
On Monday September 14, 2026 the company said it would use 'Novo' as its day-to-day name, while Novo Nordisk A/S remains its legal name. The rebrand introduced the platform 'Lasting Health Starts Now,' an updated version of the Apis bull logo, and a culture framework called The Novo Way, and the company said it would give more detail on its strategy at a Capital Markets Day in London on September 21. On Wednesday September 16, Novo and Anthropic announced a collaboration under which Novo will test Anthropic's Claude Science in research and development workflows; financial terms were not disclosed. On Thursday September 17, Novo signed a multi-target discovery and license agreement with Orbis Medicines, a Copenhagen and Lausanne company that designs oral macrocycle drugs, worth up to $1.4 billion in upfront and milestone payments plus tiered royalties, along with a strategic investment of undisclosed size. Orbis's chief executive said its macrocycles have reached up to 18% oral bioavailability in preclinical studies.
Novo set out its 2030 ambitions at the Capital Markets Day in London on Monday September 21, 2026: launch more than five multi-blockbusters, run at least five Phase 3 programs in obesity and diabetes and at least five in other therapy areas, serve more than 60 million patients, build capacity to serve 10 times more people with obesity on oral GLP-1, keep a broadly stable operating margin, and grow revenue from 2026 to 2030 in line with industry peers. It also targets more than DKK 150 billion (about $23 billion) in pipeline sales in 2035 and said the ambitions are not financial guidance. Management said CagriSema would launch early next year, followed by standalone cagrilintide and high-dose CagriSema in 2028, with zenagamtide planned in oral and injectable forms. Shares fell as much as 9% during the day, BNN Bloomberg reported, as management faced questions on pricing and dealmaking.
Eight days ahead of EASL Congress 2026 in Barcelona (May 27-30), Novo Nordisk released new analyses from the Phase 3 ESSENCE program showing semaglutide 2.4 mg holds a favorable hepatic safety profile across MASH subgroups, including the first dedicated Japanese MASH cohort and a women-in-menopause subset. Gastrointestinal events remained the leading adverse-event signal, with small discontinuation rates. MASH affects an estimated 250 million people globally with roughly 9 in 10 cases undiagnosed; the trial data reinforce the FDA's August 2025 MASH-with-fibrosis approval and broaden the prescribing case ahead of the EASL plenaries.
5W Public Relations published the fourth installment of its AI Visibility Index, finding two manufacturers — Novo Nordisk and Eli Lilly — account for nearly 100% of GLP-1-class citations inside ChatGPT, Claude, Perplexity, and Google AI Overviews. Five products — Wegovy, Zepbound, Ozempic, Mounjaro, and Saxenda — capture about 57% of all weight-loss-and-metabolic-health category citations. Founder Ronn Torossian attributes the citation moat to peer-reviewed clinical data cadence, named-author editorial coverage, and regulatory events treated as content events, with content velocity outpacing the broader news cycle.
Novo Nordisk's Executive Vice President for International Operations Emil Kongshøj Larsen told CNBC May 18 the company is preparing to go 'all in' on launching its Wegovy pill outside the US, with UK, Germany, and Denmark at the front of the international queue. The company disclosed cumulative US Wegovy pill prescriptions have crossed 2 million in the 18 weeks since the January 5 launch — roughly double the >1M figure CEO Maziar Doustdar shared on May 14. Larsen's quote: 'When we launch, we'll go all in.' The international expansion lands as Novo's full-year 2026 guidance still calls for revenue and profit declines between 4% and 12%, but the company hiked guidance slightly last week after Q1 oral semaglutide sales beat expectations. The international Wegovy pill timing matters for Lilly's Foundayo (orforglipron), which had its US PBM coverage activate mid-May but has no near-term international launch date.
Even with the first weekly Wegovy pill prescription decline since launch (~143K to ~137K week-ending May 8), the total Wegovy franchise (injectable + pill) climbed 1.3% week-over-week to approximately 446,000 prescriptions per the Fierce Pharma IQVIA tracker. Market share in the US obesity GLP-1 segment ticked up 0.1 percentage points to 40.5%. The injectable Wegovy 2.4 mg and Wegovy HD 7.2 mg formulations remain Novo's commercial anchor; the pill is the growth narrative. The 1.3% w/w injectable Wegovy growth aligns with Novo's H2 2026 international expansion plans and the EU approval expected before year-end. The data also confirms Zepbound (tirzepatide for obesity) continues to grow share faster than Wegovy on an absolute volume basis — the head-to-head dynamic that Cantor Fitzgerald and Barclays both cited in their May 5 LLY price target raises.
Hims & Hers disclosed in post-Q1 commentary picked up by Stocktwits and Yahoo Finance that the company has fulfilled approximately 125,000 Wegovy shipments since the Novo Nordisk branded-distribution partnership activated on March 26, 2026 — roughly 21,000 per week in operational terms. The volume signals materially stronger Wegovy uptake through the Hims platform than the Q1 print's $608M revenue figure suggested, with most of the contribution landing in Q2 books. Subscriber count held at 2.6M (+9% YoY), monthly average revenue per subscriber dropped to $80 from $85 on the product-mix shift, and full-year guidance was raised to $2.8-3.0B revenue. Deutsche Bank's George Hill trimmed his target to $25 from $28 (Hold). The 'Netflix of healthcare' framing from major investor Cathie Wood persists despite the post-print drop; HIMS shares partially recovered to $29.14 in early-week trading.
Hims & Hers shares fell ~13% after the May 11 Q1 print as $608.1M revenue missed the $616.9M consensus and gross margin compressed from 73% to 65% on the compounded-semaglutide wind-down. JPMorgan trimmed its price target to $33 from $35 (Overweight reaffirmed); Canaccord raised to $32 from $30 (Buy). The Motley Fool published a 'Is HIMS Stock a Buy After Latest Dip?' analysis on May 14 framing the post-print decline as a buying opportunity, citing the 9% subscriber growth to 2.6M, the raised full-year guide ($2.8-3.0B revenue, $275-350M Adjusted EBITDA), and the structural lift from the Novo Nordisk branded-Wegovy distribution deal landing in Q2 books. The split between bullish and cautious analyst takes captures the central tension: high-growth telehealth navigating a margin-dilutive product transition.
Novo Nordisk's CagriSema REDEFINE 1 cardiovascular sub-analyses, presented at ECO 2026 on Thursday May 14, layered onto the May 12 body-composition data. At week 68, CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) reduced systolic blood pressure by 10.9 mmHg vs 8.8 with semaglutide alone and 2.1 with placebo. High-sensitivity C-reactive protein dropped 68.9% vs 55.4% (semaglutide) and 16.0% (placebo). The 10-year predicted atherosclerotic cardiovascular disease risk decreased meaningfully on CagriSema versus all comparators, with fewer participants on CagriSema falling into the intermediate-to-high-risk category. The sub-analyses sharpen the combination-therapy case beyond the 22.7% mean weight-loss headline.
Novo Nordisk CEO Mike Doustdar confirmed on the May 6 Q1 analyst call and in May 14 follow-up commentary that the Wegovy pill has surpassed 1 million cumulative US users 16 weeks after the January 5, 2026 launch. The pill posted DKK 2.26B (~$354M) in Q1 sales (nearly 2x analyst consensus) on roughly 1.3 million Q1 prescriptions. Wegovy now holds 65% of all new US GLP-1 prescriptions per the Q1 IQVIA data. International expansion is targeted for H2 2026 with EU approval anticipated before year-end. The pill ramp is the cleanest near-term commercial signal for Novo against Lilly's tirzepatide franchise (Mounjaro/Zepbound), which displaced Keytruda as the world's #1 best-selling drug in Q1 2026.
A second body-composition substudy from REDEFINE 1 presented May 14 at ECO 2026 broke out the DXA subgroup by treatment arm. At week 68, CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) produced -23.9% weight reduction in the DXA subgroup, compared with -16.6% on semaglutide 2.4 mg alone, -15.0% on cagrilintide 2.4 mg alone, and -2.8% on placebo. The fat-mass-to-lean-tissue ratios were favorable across all active arms: 66.9% fat-mass contribution on CagriSema, 69.7% on semaglutide, 62.9% on cagrilintide. The cagrilintide monotherapy arm is the first head-to-head body-composition signal for amylin-only therapy at clinically meaningful weight-loss levels — relevant to Zealand and Roche's petrelintide Phase 3 program and the broader amylin-versus-incretin debate.
Novo Nordisk presented new OASIS 4 subanalyses of the Wegovy pill (oral semaglutide 25 mg) at ECO 2026 on May 13. Nearly one third (29%) of patients were classified as 'early responders' — losing at least 10% body weight by week 16 — and continued treatment to 64 weeks for a mean 21.6% body weight loss vs 13.2% at four months. A separate physical function analysis showed 77.3% of patients with poor baseline physical function achieved clinically meaningful improvement (bending over, standing comfortably, staying active) vs 42.9% on placebo. The data adds to the OASIS 4 February 2026 16.6% mean weight-loss headline by stratifying patients on early response — a likely tool for prescribers thinking about dose escalation and persistence.
An ORION indirect treatment comparison presented at ECO 2026 on May 13 framed the head-to-head competition between Novo's Wegovy pill (oral semaglutide 25 mg) and Lilly's Foundayo (orforglipron 36 mg). The Wegovy pill delivered statistically significant greater mean weight loss than orforglipron, with patients on orforglipron showing approximately 14x higher odds of discontinuing treatment due to gastrointestinal side effects. The May 13 framing complements Novo's Q1 print disclosure that Wegovy holds 65% of all new US GLP-1 prescriptions; CEO Mike Doustdar's CNBC commentary called the moment a 'turnaround situation' for the Danish company. The ORION ITC matters as a prescriber-decision tool given the two compounds are now the only two FDA-approved oral GLP-1s for chronic weight management.
Novo Nordisk Q1 management commentary delivered alongside the ECO 2026 data updates confirmed that the Wegovy pill (oral semaglutide 25 mg) will launch in select international markets in the second half of 2026 with European approval expected before year-end. The international rollout follows the January 5 US launch that delivered DKK 2.26B (~$354M) in Q1 sales — nearly double the DKK 1.16B analyst consensus — on roughly 1.3 million Q1 prescriptions and >2M cumulative US prescriptions. Wegovy now holds 65% of all new US GLP-1 prescriptions; Novo tightened its full-year guidance to a 4-12% sales decline (from 5-13%). The international expansion is the inflection point for Novo's competitive positioning vs Lilly's Foundayo and the next-generation Mounjaro/Zepbound franchise.
Novo Nordisk's CagriSema REDEFINE 1 treatment-target analysis presented as an oral presentation at ECO 2026 on May 12 reported that the cagrilintide + semaglutide combination drove a higher percentage of participants to clinically meaningful BMI and waist-to-height ratio (WHtR) targets than any monotherapy or placebo arm. 50.7% of CagriSema-treated participants reached BMI <30 at week 68 vs 10.2% on placebo, and participants reaching BMI <27 plus WHtR <0.53 showed normalization of cardiometabolic parameters at higher rates than non-achievers. A companion REDEFINE 1 cardiovascular risk analysis scheduled for May 14 ECO presentation tracks predicted atherosclerotic CVD risk reduction. The data complements the May 12 body-composition substudy (35.7% fat-mass loss vs 14.4% lean tissue loss).
Sector stock reaction across May 12-13: Novo Nordisk ADRs popped roughly 6% premarket May 12 on the early-responder + women's-data combination and the OASIS 4 mobility analyses; Eli Lilly traded flat as the SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN dual publication confirmed expected maintenance positioning rather than producing fresh upside surprises. Analysts noted the broader 'long-term treatment' thesis — that GLP-1 obesity drugs are chronic-disease medications, not short courses — got concrete trial backing this week between SURMOUNT-MAINTAIN, ATTAIN-MAINTAIN, and STEP UP early-responder analyses. The week's narrative shift sets up the May 14-15 ECO Day 3+4 cycle and the May 29-June 2 ASCO 2026 meeting in Chicago — where peptide-drug conjugates (Bicycle BT8009, Avacta AVA6000, Pfizer FAP-Dox) take the next round of clinical-data spotlights.
A post-hoc analysis of the Phase 3 STEP UP trial presented Tuesday May 12 at ECO 2026 identified an 'early responder' subgroup — patients who lost at least 15% body weight within the first 24 weeks. About 27% of patients on the higher-dose Wegovy 7.2 mg dose met that threshold vs 21% on the 2.4 mg dose and 3% on placebo. Early responders went on to lose a mean 27.7% body weight at week 72 (vs the 21% headline mean across all 7.2 mg patients). The analysis also confirmed that 84% of weight loss across both Wegovy doses came from fat mass, with muscle function preserved. The data sharpens the case for early-response-based dose decisions in the post-launch real-world workflow.
A second post-hoc analysis of STEP UP presented Tuesday found Wegovy 7.2 mg delivered consistent weight loss across reproductive life stages: 22.6% premenopausal, 19.7% perimenopausal, 19.8% postmenopausal, with 41.4% of premenopausal women hitting ≥25% loss. Waist-circumference reductions: 17.5%, 15.6%, 15.3% respectively. Separately, a real-world analysis of 34,000+ women showed that those taking Wegovy had a 42-45% lower migraine risk and a 25% lower depression risk starting six months in versus those on menopausal hormone therapy alone. The real-world data lands as observational signals that warrant prospective study — not as proof of causation — but reinforces the cardiovascular and quality-of-life narrative for the women's-health subgroup.
A prespecified body-composition substudy of REDEFINE 1 presented at ECO 2026 reported that 252 participants on CagriSema 2.4 mg/2.4 mg (semaglutide + cagrilintide) achieved a 35.7% relative reduction in fat mass and a 14.4% reduction in lean soft-tissue mass at week 68 — compared with 5.7% and 4.3% on placebo. The headline 22.7% mean weight reduction in REDEFINE 1 (NEJM publication June 2025) thus broke down with a fat-mass-to-lean-tissue ratio of roughly 2.5:1, a more favorable body-composition profile than the typical 1.5-2:1 ratio reported for GLP-1 monotherapy. The data builds the case for combination amylin-GLP-1 therapy as preferentially fat-selective.
Hims & Hers reported Q1 2026 after market close May 11: revenue $608.1M (+4% YoY vs $586M prior year), missing the $616.9M consensus; subscribers up 9% to 2.6M; net loss of $92.1M ($0.41/share) vs $49.5M net income in Q1 2025. Gross margin compressed from 73% to 65% on the strategic pivot away from compounded semaglutide toward branded Novo Nordisk Wegovy/Ozempic supply (live since March 26). Q1 closed March 31 — meaningful Wegovy revenue contribution lands in Q2. Full-year 2026 guidance was raised: revenue to $2.8-3.0B and Adjusted EBITDA to $275-350M. The company is keeping limited compounded GLP-1 access alive alongside branded supply, threading the FDA April 30 503B bulks-list proposal.